At Revere, we are striving to help cancer patients with advanced disease by developing drugs that inhibit Rho GTPase cell signaling proteins, such as Rac1. These proteins have been long recognized to play a critical role in promoting tumor progression, metastasis and resistance to standard of care.  

Our proprietary Rho GTPase platform is designed to establish a pipeline of first-in-class drugs to address areas of high, unmet needs for cancer patients.